Skip to content

Study on the Efficacy and Tolerance of a New Anti-regurgitation Infant Formula (STELLAR)

Study on the Efficacy and Tolerance of a New Anti-regurgitation Infant Formula: a Double-blind, Randomized, Controlled, International, Multi-centric Clinical Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04358146
Acronym
STELLAR
Enrollment
346
Registered
2020-04-24
Start date
2023-03-17
Completion date
2026-12-03
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroesophageal Reflux in Children

Keywords

Reflux

Brief summary

The aim of the study is to assess the effectiveness of this new formula on regurgitations and secondarily its effect on digestive tolerance through a randomized, controlled, double-blind trial against a comparator.

Detailed description

The study duration is 1 month and 2 days. It is possible to add 2 additional months (optional). The 2 first days (from D-3 to D0) correspond to the pre-selection period. These 2 days are followed by the follow-up month (from D0 to D30). It is possible to add an optional follow up of 2 months (form D30 to D90).

Interventions

Exclusive formula feeding with the new infant formula thickened with fibers

OTHERInfant formula thickened with locust bean gum

Exclusive formula feeding with the formula thickened with locust bean

Sponsors

United Pharmaceuticals
Lead SponsorINDUSTRY
Statitec
CollaboratorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
2 Weeks to 4 Months
Healthy volunteers
No

Inclusion criteria

* ≥ 2 regurgitation episodes per day during the last 2 weeks and ≥ 4 regurgitation episodes per day in average during the last 2 days, * exclusive or predominant formula feeding * whose parents signed informed consent

Exclusion criteria

* preterm infants or birthweight \<2500g * Post enteritis lactose intolerance * Suspected or diagnosed cow's milk protein allergy requiring an eviction diet * Use of medications that may interfere with regurgitation or gastrointestinal transit (such as alginates, laxatives, antibiotics...). All these medications have to be stopped at least 7 days before inclusion visit (V1) * Infants presenting with any situation which, according to the investigator, may interfere with the study participation, or lead to a particular risk for the subject

Design outcomes

Primary

MeasureTime frameDescription
Frequency of regurgitationDay 14Decrease of the daily number of regurgitation between baseline and day 14

Secondary

MeasureTime frameDescription
Frequency of regurgitationsDay 30, Day 90Change in the daily number of regurgitation between baseline and day 30 / day 90
Severity of regurgitation episodesDay 14, Day 30, Day 90Severity of regurgitations will be assessed using the adapted Vandenplas' score (range: 0 to 6; higher scores indicate more severe regurgitation)
Stools' frequencyDay 14, Day 30, Day 90Average daily stool's number
Stools' consistencyDay 14, Day 30, Day 90The Amsterdam Infant Stool Scale (AISS) (consistency categories: A \[watery\] to D \[hard\]; higher categories indicate firmer stools)
Frequency of diarrheaDay 14, Day 30, Day 90Frequency : Occurence of diarrhea
Severity of diarrheaDay 14, Day 30, Day 90Severity of diarrhea assessed using a study-specific score calculated as the sum of the products of each watery stool and its volume over 2 days (minimum score: 6; no upper limit; higher scores indicate more severe diarrhea)
Frequency of constipationDay 14, Day 30, Day 90Occurence of constipation
Severity of constipationDay 14, Day 30, Day 90Severity of constipation assessed using a study-specific score (range: 1 to 3; higher scores indicate more severe constipation)
Crying timeDay 14, Day 30, Day 90Crying time reported by parents in class (Min : Less than 10 min / Max : 3h or more)
Feeding refusalDay 14, Day 30, Day 90Percentage of parents reporting feeding refusal by frequency of occurence (Never / Rarely / Sometimes / Often / Always)
Abnormal posturingDay 14, Day 30, Day 90Percentage of parents reporting abnormal posturing by frequency of occurence (Never / Rarely / Sometimes / Often / Always)
Sleep qualityDay 14, Day 30, Day 90Percentage of parents reporting poor sleep quality (Excellent / Good / Fair / Poor)
Anthropometric parameters - WeightDay 14, Day 30, Day 90Body weight measured in kilograms (kg)
Anthropometric parameters - LengthDay 14, Day 30, Day 90Body length measured in centimeters (cm)
Anthropometric parameters - Head circumferenceDay 14, Day 30, Day 90Head circumference measured in centimeters (cm)
Anthropometric parameters - BMIDay 14, Day 30, Day 90Body mass index calculated as kg/m²
Anthropometric parameters - Weight-for-height z-scoreDay 14, Day 30, Day 90Weight-for-height z-score calculated according to WHO Child Growth Standards
Use of drug treatmentsDay 14, Day 30, Day 90Frequency of use of proton-pump inhibitors, prokinetics, other GERD treatment
Parents' satisfactionDay 14, Day 30, Day 90Parental satisfaction assessed using a 5-point Likert scale (Very satisfied, Fairly well satisfied, Somewhat dissatisfied, Very dissatisfied, No opinion)
Investigator's satisfactionDay 14, Day 30, Day 90Investigator satisfaction assessed using a 5-point Likert scale (Very satisfied, Fairly well satisfied, Somewhat dissatisfied, Very dissatisfied, No opinion)

Countries

Belgium, France, Greece, Italy

Contacts

CONTACTMagalie JEGAT
m.jegat@novalac.com+330155372222
CONTACTANNE-SOPHIE GARREAU
as.garreau@novalac.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 5, 2026